Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nagendra R, Tirumali"'
Autor:
Shaker R. Dakhil, Gabriel N. Hortobagyi, Theodore A. Vandenberg, Hannah M. Linden, William E. Barlow, Nagendra R. Tirumali, Daniel F. Hayes, Kathy S. Albain, Rita S. Mehta, Danika L. Lew, Julie Gralow, Robert B. Livingston
Publikováno v:
The New England journal of medicine, vol 380, iss 13
BackgroundWe previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromata
Autor:
Rita S. Mehta, Kelley M. Kidwell, James M. Rae, Shaker R. Dakhil, William E. Barlow, Daniel F. Hayes, Theodore A. Vandenberg, Robert B. Livingston, Nagendra R. Tirumali, Gabriel N. Hortobagyi, Julie Gralow, Daniel L. Hertz, Kathy S. Albain
Publikováno v:
British Journal of Clinical Pharmacology. 81:1134-1141
AIMS In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer. Here we report a pharmacokinetic subset analysis investigat
Autor:
Daniel F. Hayes, Kathy S. Albain, Robert B. Livingston, William E. Barlow, Nagendra R. Tirumali, Gabriel N. Hortobagyi, Theodore A. Vandenberg, Shaker R. Dakhil, Danika L. Lew, Julie Gralow, Rita S. Mehta
Publikováno v:
New England Journal of Medicine. 367:435-444
The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more effective than anastrozole alone in patients with
Autor:
Daniel L, Hertz, William E, Barlow, Kelley M, Kidwell, Kathy S, Albain, Ted A, Vandenberg, Shaker R, Dakhil, Nagendra R, Tirumali, Robert B, Livingston, Julie, Gralow, Daniel F, Hayes, Gabriel N, Hortobagyi, Rita S, Mehta, James M, Rae
Publikováno v:
British journal of clinical pharmacology. 81(6)
In the SWOG S0226 trial the combination of anastrozole plus fulvestrant (n = 349) was superior to anastrozole alone (n = 345) in hormone receptor (HR)-positive metastatic breast cancer. Here we report a pharmacokinetic subset analysis investigating a